The triple combination also increased tumor-specific CD8 T cells systemically compared to ISF35 monotherapy or anti-CTLA-4 plus anti-PD-1 double therapy (Fig. 6d), supporting the role of tumor-specific CD8 T cells (Fig. 3a) in both local and distant tumor suppression. The gene discussed is CD8A; the disease is neoplasm.